Weight Loss and Safety of Semaglutide in Korean Adults Living With Obesity
Follows adults in Korea with obesity who are prescribed semaglutide by their doctors.
Key facts
- Who runs it
- Novo Nordisk A/S
- Where
- Busan, Daegu, Daejeon, Goyang-si, Gwangmyeong-si, Gyeonggi-do, Seongnam-si, Seongnam-si, Gyeonggi-do, Seoul, Suwon, Uijeongbu-si, Uijeongbu-si, Gyeonggi-do, Yangsan, and Yongin-si, South KoreaSee the 18 sites
- Trial code
- NCT07280221
- U1111-1306-1595
- Registry title
- WEgovy Real World Assessment of Weight Loss in Korea
- Status
- Enrolling by invitation
- People taking part
- 500 people, planned
- Started
- 10 Nov 2025
- Expected to end
- 31 Oct 2027
- Type of study
- Observational
- Treatments tested
- Semaglutide
- Record updated
- 30 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity in Korea who are starting Wegovy (semaglutide) for the first time as part of their normal care. It follows weight change and safety for about 52 weeks.
- Age
- 19 years or older
- Sex
- Men and women can join.
- Disease stage
- Obesity.
- Earlier treatment
- Must be starting Wegovy (semaglutide) for the first time, as the label says. The decision to treat was made by the patient and doctor before and apart from joining the study. Must not have taken part before in a clinical study with Wegovy (semaglutide).
Main reasons for not taking part
- Took part before in a clinical study that included Wegovy (semaglutide)
- Pregnant, breast-feeding, or planning to become pregnant
- Able to have children but not using adequate contraception
- Mental incapacity, unwillingness or language barriers that stop understanding or co-operation
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
- The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study
- Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label
- Male or female, aged ≥ 19 years at the time of signing the informed consent
Who cannot take part
- Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study
- Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice)
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation
Where in South Korea
- Dong-A University HospitalBusan, South KoreaEnrolling by invitation
- Inje University Haeundae Paik HospitalBusan, South KoreaEnrolling by invitation
- Keimyung University Dongsan HospitalDaegu, South KoreaEnrolling by invitation
- Daejeon Endo Internal Medicine ClinicDaejeon, South KoreaEnrolling by invitation
- Konyang University HospitalDaejeon, South KoreaEnrolling by invitation
- National Health Insurance Corporation Ilsan HospitalGoyang-si, South KoreaEnrolling by invitation
- Chung-Ang University Gwangmyeong HospitalGwangmyeong-si, Gyeonggi-do, South KoreaEnrolling by invitation
- Seoul National University Bundang HospitalSeongnam-si, South KoreaEnrolling by invitation
- CHA Bundang Medical CenterSeongnam-si, Gyeonggi-do, South KoreaEnrolling by invitation
- Seoul Happiness Clinic of internal medicineSeongnam-si, Gyeonggi-do, South KoreaEnrolling by invitation
- Chung ang University HospitalSeoul, South KoreaEnrolling by invitation
- Ewha Womans University Seoul HospitalSeoul, South KoreaEnrolling by invitation
- Korea University Guro HospitalSeoul, South KoreaEnrolling by invitation
- Ajou University HospitalSuwon, South KoreaEnrolling by invitation
- The Catholic University of Korea Uijeongbu St. Mary's HospitalUijeongbu-si, South KoreaEnrolling by invitation
- Uijeongbu Eulji university HospitalUijeongbu-si, Gyeonggi-do, South KoreaEnrolling by invitation
- Pusan National University Yangsan HospitalYangsan, South KoreaEnrolling by invitation
- Yongin Severance HospitalYongin-si, South KoreaEnrolling by invitation
About the trial
What the trial wants to find out
This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.
The group in the trial
- Once weekly Wegovy
Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.
Treatment: Semaglutide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- WEgovy Real World Assessment of Weight Loss in Korea (WE-WALK): a Multi-centre, Prospective, Single-arm, Nonintervention Study to Investigate the Effectiveness and Safety of Once-weekly Semaglutide 2.4 mg for People Living With Obesity in Routine Clinical Practice in Korea
- Plain-language title
- Weight Loss and Safety of Semaglutide in Korean Adults Living With ObesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 September 2026